哌拉西林-他唑巴坦对比美罗培南治疗产超广谱β-内酰胺酶大肠埃希菌或肺炎克雷伯菌血流感染的随机临床试验
该非劣效性随机临床试验纳入391例对头孢曲松不耐药但对哌拉西林-他唑巴坦敏感的E coli或K pneumoniae血流感染患者,比较哌拉西林-他唑巴坦与美罗培南的30天全因死亡率。
要点
- 哌拉西林-他唑巴坦未能证明在30天死亡率上非劣效于美罗培南。
- 哌拉西林-他唑巴坦组30天死亡风险比美罗培南组高8.6%。
- 研究结果不支持在该人群中使用哌拉西林-他唑巴坦替代碳青霉烯类。
核心结论
- 对于头孢曲松耐药的大肠埃希菌或肺炎克雷伯菌血流感染患者,哌拉西林-他唑巴坦对比美罗培南未能达到30天死亡率的非劣效性。
- 研究结果不支持在该临床情境中使用哌拉西林-他唑巴坦。
研究设计与样本
- 非劣效性、平行组、随机临床试验,于2014年2月至2017年7月在9个国家26个中心纳入住院患者。
- 筛查1646例患者,最终391例随机分配,其中379例纳入主要分析人群。
- 患者按1:1随机接受静脉哌拉西林-他唑巴坦4.5g每6小时(n=188)或美罗培南1g每8小时(n=191),疗程至少4天、最长14天。
- 主要结局为随机化后30天全因死亡率,非劣效性界值为5%。
主要发现
- 哌拉西林-他唑巴坦组30天死亡率为12.3%(23/187),美罗培南组为3.7%(7/191)。
- 符合方案人群分析结果与主要分析一致。
- 非致命性严重不良事件在哌拉西林-他唑巴坦组为2.7%(5/188),美罗培南组为1.6%(3/191)。
临床怎么用
- 对于头孢曲松耐药的大肠埃希菌或肺炎克雷伯菌血流感染,不应使用哌拉西林-他唑巴坦作为碳青霉烯类的替代方案。
- 临床决策时应优先考虑美罗培南等碳青霉烯类药物治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Extended-spectrum β-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum β-lactamase producers. OBJECTIVES: To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. DESIGN, SETTING, AND PARTICIPANTS: Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. Adult patients were eligible if they had at least 1 positive blood culture with E coli or Klebsiella spp testing nonsusceptible to ceftriaxone but susceptible to piperacillin-tazobactam. Of 1646 patients screened, 391 were included in the study. INTERVENTIONS: Patients were randomly assigned 1:1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality at 30 days after randomization. A noninferiority margin of 5% was used. RESULTS: Among 379 patients (mean age, 66.5 years; 47.8% women) who were randomized appropriately, received at least 1 dose of study drug, and were included in the primary analysis population, 378 (99.7%) completed the trial and were assessed for the primary outcome. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1-sided 97.5% CI, -∞ to 14.5%]; P = .90 for noninferiority). Effects were consistent in an analysis of the per-protocol population. Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group and 3 of 191 (1.6%) in the meropenem group. CONCLUSIONS AND RELEVANCE: Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality. These findings do not support use of piperacillin-tazobactam in this setting. TRIAL REGISTRATION: anzctr.org.au Identifiers: ACTRN12613000532707 and ACTRN12615000403538 and ClinicalTrials.gov Identifier: NCT02176122.
引用
- Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018. PMID: 30208454. doi:10.1001/jama.2018.12163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。